Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06680830 · ClinicalTrials.gov registry record · Phase 2

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

A Phase 2 study of Parkinson Disease and Parkinson, sponsored by Neuron23.

Recruiting
Registry status
Phase 2
Development phase
150
Enrollment target
20
Study locations

NCT06680830 is a Phase 2 study of Parkinson Disease and Parkinson that is actively recruiting participants, run by Neuron23. The registered enrollment target is 150 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06680830, a Phase 2 study of Parkinson Disease and Parkinson, is actively recruiting participants, sponsored by Neuron23.

RECRUITING
Registry status
Phase 2
Development phase
150 participants
Enrollment target
20
Study locations

Study Summary

The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway.

Conditions Studied

Parkinson Disease Parkinson Idiopathic Parkinson Disease Parkinson Disease, Idiopathic Early Parkinson Disease (Early PD)

Interventions

  • OTHER Placebo
  • DRUG NEU-411

Study Locations (20)

California

  • Neuro-Pain Medical Center - Fresno
  • University of California, Irvine - Irvine
  • University of California, Los Angeles - Los Angeles
  • Esperanza Clinical - Murrieta
  • Parkinson's Research Centers of America - Palo Alto - Palo Alto
  • Sutter Neuroscience Institute - Sacramento

Florida

  • Parkinson's Disease and Movement Disorders Center of Boca Raton - Boca Raton
  • University of Florida - Gainesville
  • Neurology One - Orlando
  • USF Parkinson's & Movement Disorders Clinic - Tampa

Georgia

  • Emory University - Atlanta
  • Augusta University - Augusta

Arizona

  • Banner Sun Health Research Institute - Sun City

Arkansas

  • University of Arkansas - Little Rock

Colorado

  • University of Colorado - Anschutz Medical Campus - Aurora

Illinois

  • Northwestern Medical Group, Department of Neurology - Chicago

Kansas

  • University of Kansas Medical Center - Kansas City

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2025-01-17
Est. Completion 2027-09
Phase Phase 2

Sponsor

Neuron23

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06680830

The ClinicalTrials.gov registry entry for NCT06680830 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (97% lower). The listed sponsor is Neuron23, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06680830 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT06680830 about?

NCT06680830 is a clinical study titled "A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease". The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic pr...

What is the current status of trial NCT06680830?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2025-01-17. Estimated completion is 2027-09.

What conditions does trial NCT06680830 study?

This clinical trial studies the following conditions: Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Parkinson Disease, Idiopathic, Early Parkinson Disease (Early PD).

What interventions are being tested in trial NCT06680830?

The interventions under investigation include: Placebo (OTHER), NEU-411 (DRUG).

Who is sponsoring clinical trial NCT06680830?

This trial is sponsored by Neuron23, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06680830 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinson Disease

All registered trials for this condition

Parkinson

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.